MeiraGTx Holdings PLC MGTX:NASDAQ

Last Price$8.71NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$8.10 (1)
Ask (Size)$8.74 (2)
Day Low / HighN/A - N/A
Volume240.4 K
  • Latest Stories
  • Commentary and Analysis
--Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
10:47AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Barclays Lowers MeiraGTx Holdings's Price Target to $18 From $32, Maintains Overweight Rating
10:47AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Piper Sandler Adjusts MeiraGTx Holdings' Price Target to $30 From $40, Reiterates Overweight Rating
5:06AM ET 5/13/2022 MT Newswires

MeiraGTx Holdings (MGTX) has an average rating of buy and price targets ranging from $18 to $55, according to analysts polled by Capital IQ. (MT Newswires...

MeiraGTx Holdings 2021 Net Loss Widens; Expects Sufficient Capital Through Q2 2023
8:41AM ET 3/10/2022 MT Newswires

MeiraGTx Holdings (MGTX) on Thursday reported a full-year 2021 net loss of $1.80 per diluted share, widening from a loss of $1.54 per share in 2020....

MeiraGTx Gets $30 Million Milestone Payment from Janssen Pharmaceuticals for Retinitis Pigmentosa Trial
10:32AM ET 1/27/2022 MT Newswires

MeiraGTx Holdings (MGTX) said Thursday it has received $30 million from Johnson & Johnson's (JNJ) Janssen Pharmaceuticals for achieving a clinical...

MeiraGTx Holdings Reports Positive Preliminary Data From Trial of Potential Treatment for Radiation-Induced Xerostomia
7:54AM ET 12/07/2021 MT Newswires

MeiraGTx Holdings (MGTX) on Tuesday reported positive preliminary data from a phase 1 trial of AAV-hAQP1 to treat grade 2/3 radiation-induced xerostomia, a...

MeiraGTx Holdings Q3 Loss Deepens, Revenue Rises
10:14AM ET 11/10/2021 MT Newswires

MeiraGTx Holdings (MGTX), a clinical stage gene therapy company, reported Wednesday a Q3 diluted net loss of $0.59 per share, compared with a $0.17 loss a...

Insider Sell: Meiragtx Holdings
5:40PM ET 10/21/2021 MT Newswires

Richard Giroux, CFO & COO, on October 19, 2021, sold 22,000 shares in Meiragtx Holdings (MGTX) for $461,777. Following the Form 4 filing with the SEC,...

Insider Sell: Meiragtx Holdings
5:49PM ET 10/20/2021 MT Newswires

Alexandria Forbes, Director, President and CEO, on October 18, 2021, sold 30,000 shares in Meiragtx Holdings (MGTX) for $520,687. Following the Form 4...

Insider Sell: Meiragtx Holdings
5:44PM ET 10/20/2021 MT Newswires

Stuart Naylor, Chief Development Officer, on October 18, 2021, sold 12,000 shares in Meiragtx Holdings (MGTX) for $215,400. Following the Form 4 filing...